» Articles » PMID: 33106863

Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study

Abstract

Introduction: This study aims to assess the association of piperacillin/tazobactam and meropenem minimum inhibitory concentration (MIC) and beta-lactam resistance genes with mortality in the MERINO trial.

Methods: Blood culture isolates from enrolled patients were tested by broth microdilution and whole genome sequencing at a central laboratory. Multivariate logistic regression was performed to account for confounders. Absolute risk increase for 30-day mortality between treatment groups was calculated for the primary analysis (PA) and the microbiologic assessable (MA) populations.

Results: In total, 320 isolates from 379 enrolled patients were available with susceptibility to piperacillin/tazobactam 94% and meropenem 100%. The piperacillin/tazobactam nonsusceptible breakpoint (MIC >16 mg/L) best predicted 30-day mortality after accounting for confounders (odds ratio 14.9, 95% confidence interval [CI] 2.8-87.2). The absolute risk increase for 30-day mortality for patients treated with piperacillin/tazobactam compared with meropenem was 9% (95% CI 3%-15%) and 8% (95% CI 2%-15%) for the original PA population and the post hoc MA populations, which reduced to 5% (95% CI -1% to 10%) after excluding strains with piperacillin/tazobactam MIC values >16 mg/L. Isolates coharboring extended spectrum β-lactamase (ESBL) and OXA-1 genes were associated with elevated piperacillin/tazobactam MICs and the highest risk increase in 30-day mortality of 14% (95% CI 2%-28%).

Conclusions: After excluding nonsusceptible strains, the 30-day mortality difference from the MERINO trial was less pronounced for piperacillin/tazobactam. Poor reliability in susceptibility testing performance for piperacillin/tazobactam and the high prevalence of OXA coharboring ESBLs suggests that meropenem remains the preferred choice for definitive treatment of ceftriaxone nonsusceptible Escherichia coli and Klebsiella.

Citing Articles

Evaluation of piperacillin-tazobactam disks using contemporary Enterobacterales isolates suggests the need for disk potency optimization.

Khan A, Manuel C, Maynard R, Humphries R J Clin Microbiol. 2025; 63(2):e0159924.

PMID: 39791897 PMC: 11837518. DOI: 10.1128/jcm.01599-24.


An Update on Recent Clinical Trial Data in Bloodstream Infection.

Stewart A, Simos P, Sivabalan P, Escola-Verge L, Garnham K, Isler B Antibiotics (Basel). 2024; 13(11).

PMID: 39596730 PMC: 11591257. DOI: 10.3390/antibiotics13111035.


Prevalence and clinical significance of the genotypic carriage among ESBL phenotype-negative and clinical isolates in bacteremia: a study in a Malaysian tertiary center.

Lau C, Neoh H, Periyasamy P, Tg Abu Bakar Sidik T, Tan T, Ramli R Front Cell Infect Microbiol. 2024; 14:1429830.

PMID: 39512590 PMC: 11540778. DOI: 10.3389/fcimb.2024.1429830.


Innovative approaches in phenotypic beta-lactamase detection for personalised infection management.

Lawrence J, OHare D, van Batenburg-Sherwood J, Sutton M, Holmes A, Rawson T Nat Commun. 2024; 15(1):9070.

PMID: 39433753 PMC: 11494114. DOI: 10.1038/s41467-024-53192-7.


Clinical Outcomes of Patients with AmpC-Beta-Lactamase-Producing Enterobacterales Bacteremia Treated with Carbapenems versus Non-Carbapenem Regimens: A Single-Center Study.

Shalabi O, Kashat L, Murik O, Zevin S, Assous M, Ben-Chetrit E Antibiotics (Basel). 2024; 13(8).

PMID: 39200009 PMC: 11350690. DOI: 10.3390/antibiotics13080709.